Decreased influenza-specific B cell responses in rheumatoid arthritis patients treated with anti-tumor necrosis factor

Abstract

IntroductionAs a group, rheumatoid arthritis (RA) patients exhibit increased risk of infection, and those treated with anti-tumor necrosis factor (TNF) therapy are at further risk. This increased susceptibility may result from a compromised humoral immune response. Therefore, we asked if short-term effector (d5-d10) and memory (1 month or later) B cell responses to antigen were compromised in RA patients treated with anti-TNF therapy.MethodsPeripheral blood samples were obtained from RA patients, including a subset treated with anti-TNF, and from healthy controls to examine influenza-specific responses following seasonal influenza vaccination. Serum antibody was measured by hemagglutination inhibition assay. The frequency of influenza vaccine-specific antibody secreting cells and memory B cells was measured by EliSpot. Plasmablast (CD19+IgD-CD27hiCD38hi) induction was measured by flow cytometry.ResultsCompared with healthy controls, RA patients treated with anti-TNF exhibited significantly decreased influenza-specific serum antibody and memory B cell responses throughout multiple years of the study. The short-term influenza-specific effector B cell response was also significantly decreased in RA patients treated with anti-TNF as compared with healthy controls, and correlated with decreased influenza-specific memory B cells and serum antibody present at one month following vaccination.ConclusionsRA patients treated with anti-TNF exhibit a compromised immune response to influenza vaccine, consisting of impaired effector and consequently memory B cell and antibody responses. The results suggest that the increased incidence and severity of infection observed in this patient population could be a consequence of diminished antigen-responsiveness. Therefore, this patient population would likely benefit from repeat vaccination and from vaccines with enhanced immunogenicity.

Vedolizumab affects antibody responses to immunisation selectively in the gastrointestinal tract: randomised controlled trial results

“…Indeed, impaired response to HBV has been described in patients with rheumatoid arthritis receiving etanercept monotherapy 23. Other studies have yielded similar results 24 25. However, vaccination is generally considered worthwhile, as protective immunity can be achieved in most patients receiving these therapies 22 26…”

NOTCH inhibits osteoblast formation in inflammatory arthritis via noncanonical NF-κB

“…Healthy controls (n = 14) were age matched, and subjects on bisphosphonates were excluded. BMMCs and PBMCs were isolated from heparinized BM aspirate and heparinized PB by Ficoll-Hypaque density gradient centrifugation (Pharmacia Biotech) (60,61). PBMCs and BMMCs were incubated with anti-human CD45 antibody-conjugated microbeads (Miltenyi Biotec).…”

Transient decrease in human peripheral blood myeloid dendritic cells following influenza vaccination correlates with induction of serum antibody

“…Based on subject willingness, availability, and logistical constraints, a subset of subjects (n=6) provided three additional samples following 2009–2010 TIV immunization; one obtained on day five to day seven post-vaccination, another obtained day eight to day ten post-vaccination, and a final sample collected 1 month post-vaccination. PBMC and serum were isolated and cryopreserved as previously described (13). Briefly, PBMC were isolated within two hours of sampling using CPT tubes (Becton Dickinson, Franklin Lakes, NJ, USA).…”